<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00366626</url>
  </required_header>
  <id_info>
    <org_study_id>P50AA010761</org_study_id>
    <nct_id>NCT00366626</nct_id>
  </id_info>
  <brief_title>Effectiveness of Naltrexone Versus Placebo to Reduce Craving for Alcohol With Evaluation of Genetic Variability.</brief_title>
  <official_title>Alcohol Research Center Grant. Component #1: Naltrexone Effects on Alcohol Reactivity and Consumption, Evaluating the Genetic Variability of Naltrexone Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether naltrexone (an opiate blocking agent
      approved for the treatment of alcohol dependence) is more effective in the reduction of
      alcohol craving and drinking compared to placebo in individuals with particular genetic
      predisposition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      About 300 non-treatment seeking alcoholics will be recruited through advertisement and paid
      for their participation. They will be assessed, subtyped for mu-opiate receptor and
      catechol-O-methyltransferase (COMT) allelic variants and 88 individuals (44 with the more
      common AA gene and 44 with either an AG or GG gene) will be randomly assigned to take either
      naltrexone (50 mg/day) or a matching placebo for 7 days. Since the val and met alleles of the
      catechol-O-methyltransferase (COMT) gene are each present in about 50% of the population they
      will be equally distributed by urn randomization to all opiate allele and treatment groups.
      After 5 days of natural drinking and one day of abstinence, subjects will undergo an alcohol
      cue-induced brain activity scan using well-established fMRI techniques on Day 6 of study
      drug. The following day all subjects will receive a standard dose (gender and weight
      corrected) of alcohol and be evaluated for alcohol reactivity (stimulation, sedation,
      intoxication, craving) over 40 minutes. They then will be allowed to consume up to 8
      mini-drinks over a 2-hour period. Afterwards all subjects will receive
      educational/motivational counseling regarding their alcohol use and its effects. Referral for
      treatment will be offered.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>&quot;Natural&quot; Alcohol Consumption Period; Average Number of Drinks Per Day Consumed During the 5 Day Natural (Usual Environment) Drinking Observation Period</measure>
    <time_frame>treatment days 1 - 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Limited Access Alcohol Consumption Paradigm; Total Number of Drinks Consumed</measure>
    <time_frame>On day 7 of treatment during limited access alcohol consuption in the bar/laboratory</time_frame>
    <description>Subjects were allowed to drink up to 8 alcohol drinks during 2 hours observation period being in bar/laboratory settings vs to get $2 per each not consumed drink.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Alcohol Dependence</condition>
  <arm_group>
    <arm_group_label>1.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naltrexone one capsule a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One capsule a day match to naltrexone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>Naltrexone (25 mg/day for days 1-2 and 50 mg/day for days 3-7)</description>
    <arm_group_label>1.</arm_group_label>
    <other_name>ReVia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for 7 days matched to Naltrexone</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Age 21-65. 2. Meets the DSM IV criterion for current alcohol dependence including
             &quot;loss of control over drinking&quot; (criterion 4) but does not necessarily have signs of
             physiologic dependence as expressed in criterion for tolerance development (criterion
             1) and withdrawal symptoms or use to avoid withdrawal symptoms (criterion 2).

             3. Drinks hard liquor/spirits and does not have aversion to this form of alcohol.

             4. Drinks alone (not in the presence of others) some of the time (to maximize the
             potential of drinking in the bar lab where a subject will not be in the company of
             others).

             5. Currently is not engaged in, and does not want treatment for, alcohol related
             problems.

             6. Able to read and understand questionnaires and informed consent. 7. Lives within 50
             miles of the study site. 8. Able to maintain abstinence for two days (without the aid
             of detox medications) as determined by self-report and breathalyzer measurements.

        Inclusion for fMRI imaging sub-study (see methodology section for rationale):

          1. Does not have metal objects in the head/neck.

          2. Does not have a history of claustrophobia leading to significant clinical anxiety
             symptoms.

        Exclusion Criteria:

          -  1. Currently meets DSM-IV criteria for any other psychoactive substance dependence
             disorder.

             2. History of opiate abuse or a positive urine drug screen for opiates. 3. Any
             psychoactive substance use (except marijuana and nicotine) within the last 30 days as
             evidenced by self-report and urine drug screen. For marijuana - no use within the last
             seven days.

             4. Meets DSM-IV criteria for current axis I disorders of major depression, panic
             disorder, obsessive-compulsive disorder, post-traumatic stress disorder, bipolar
             affective disorder, schizophrenia, dissociative disorders and eating disorders, any
             other psychotic disorder or an organic mental disorder.

             5. Has current suicidal ideation or homicidal ideation. 6. Need for maintenance or
             acute treatment with any psychoactive medication including anti-seizure medications.

             7. Current use of disulfiram, naltrexone, or acamprosate. 8. Clinically significant
             medical problems such as, cardiovascular, renal, gastrointestinal, or endocrine
             problems that would impair participation or limit medication ingestion.

             9. Past history of alcohol related medical illness such as gastrointestinal bleeding,
             pancreatitis, peptic ulcer, hepatic cirrhosis or alcoholic hepatitis.

             10. Hepatocellular disease indicated by elevations of SGPT Alanine transaminase(ALT)
             or SGOT Aspartate transaminase(AST) greater than 3 times normal at screening.

             11. Females of child-bearing potential who are pregnant (by urine HCG), nursing, or
             who are not using a reliable form of birth control.

             12. Has current charges pending for a violent crime (not including DUI related
             offenses).

             13. Does not have a stable living situation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond F Anton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>· Center for Drug and Alcohol Programs,· Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2006</study_first_submitted>
  <study_first_submitted_qc>August 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2006</study_first_posted>
  <results_first_submitted>April 19, 2012</results_first_submitted>
  <results_first_submitted_qc>November 2, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 3, 2012</results_first_posted>
  <last_update_submitted>May 4, 2017</last_update_submitted>
  <last_update_submitted_qc>May 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alcohol dependence</keyword>
  <keyword>Alcoholism</keyword>
  <keyword>Craving</keyword>
  <keyword>Genetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Naltrexone</title>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Naltrexone</title>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="83"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" spread="10"/>
                    <measurement group_id="B2" value="26" spread="10"/>
                    <measurement group_id="B3" value="28" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>&quot;Natural&quot; Alcohol Consumption Period; Average Number of Drinks Per Day Consumed During the 5 Day Natural (Usual Environment) Drinking Observation Period</title>
        <time_frame>treatment days 1 - 5</time_frame>
        <population>All subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone (asn40asn)</title>
            <description>Subjects with asn40asn OPRM1 SNP who got Naltrexone during he study</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone (asp40)</title>
            <description>Subjects with asp40 OPRM1 SNP who got Naltrexone during he study</description>
          </group>
          <group group_id="O3">
            <title>Placebo (asn40asn )</title>
            <description>Subjects with asn40asn OPRM1 SNP who got Placebo during he study</description>
          </group>
          <group group_id="O4">
            <title>Placebo (asp40)</title>
            <description>Subjects with asp40 OPRM1 SNP who got Placebo during he study</description>
          </group>
        </group_list>
        <measure>
          <title>&quot;Natural&quot; Alcohol Consumption Period; Average Number of Drinks Per Day Consumed During the 5 Day Natural (Usual Environment) Drinking Observation Period</title>
          <population>All subjects who were randomized.</population>
          <units>Drinks per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="1.8"/>
                    <measurement group_id="O2" value="5.7" spread="3.2"/>
                    <measurement group_id="O3" value="6.2" spread="3.4"/>
                    <measurement group_id="O4" value="6.3" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This was a 2 gene (asn40asn vs 40asp) by two medication (naltrexone vs placebo) design. The main hypothesis was that the effect of naltrexone (mean naltrexone drinking – placebo drinking) would be greater in the 40asp subjects than in the asn40asn subjects. Thus the null hypothesis there would be no gene by medication interaction. The mean difference above is then the difference in the size of the naltrexone effect in the two genotypes, equivalent to the interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.51</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.92</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>6.32</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.85</ci_lower_limit>
            <ci_upper_limit>3.69</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Limited Access Alcohol Consumption Paradigm; Total Number of Drinks Consumed</title>
        <description>Subjects were allowed to drink up to 8 alcohol drinks during 2 hours observation period being in bar/laboratory settings vs to get $2 per each not consumed drink.</description>
        <time_frame>On day 7 of treatment during limited access alcohol consuption in the bar/laboratory</time_frame>
        <population>All subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone (asn40asn)</title>
            <description>Subjects with asn40asn OPRM1 SNP who got Naltrexone during he study</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone (asp40)</title>
            <description>Subjects with asp40 OPRM1 SNP who got Naltrexone during he study</description>
          </group>
          <group group_id="O3">
            <title>Placebo (asn40asn )</title>
            <description>Subjects with asn40asn OPRM1 SNP who got Placebo during he study</description>
          </group>
          <group group_id="O4">
            <title>Placebo (asp40)</title>
            <description>Subjects with asp40 OPRM1 SNP who got Placebo during he study</description>
          </group>
        </group_list>
        <measure>
          <title>Limited Access Alcohol Consumption Paradigm; Total Number of Drinks Consumed</title>
          <description>Subjects were allowed to drink up to 8 alcohol drinks during 2 hours observation period being in bar/laboratory settings vs to get $2 per each not consumed drink.</description>
          <population>All subjects who were randomized.</population>
          <units>Total number of drinks consumed</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="2.9"/>
                    <measurement group_id="O2" value="3.8" spread="3.1"/>
                    <measurement group_id="O3" value="3.8" spread="2.8"/>
                    <measurement group_id="O4" value="3.1" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This was a 2 gene (asn40asn vs 40asp) by 2 medication (naltrexone vs. placebo)interaction analysis. The main hypothesis was that subjects who had 40asp OPRM1 allele would a greater naltrexone effect on drinking (Placebo – Naltrexxone) than the asn40asn subjects. Thus the null hypothesis was the gene by medication interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.28</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.46</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>6.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.22</ci_lower_limit>
            <ci_upper_limit>4.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Naltrexone</title>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Raymond F. Anton, Distinguished University Professor</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>843-792-1226</phone>
      <email>antonr@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

